Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History

被引：4
|
作者：
Jentzen, Walter [1 ]
Nahum, Alan E. [1 ]
Bockisch, Andreas [1 ]
Binse, Ina [1 ]
Tulchinsky, Mark [1 ]
机构：
[1] Klin Nukl Med, Hufelandstr 55, D-45122 Essen, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2017年 / 58卷 / 09期
关键词：
RADIOIODINE THERAPY;
D O I：
10.2967/jnumed.117.192872
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：1530 / 1530
页数：1
相关论文
共 35 条
  • [1] Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History REPLY
    Deandreis, Desiree
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (09) : 1531 - 1531
  • [2] Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (05) : 697 - 699
  • [3] Dosimetric approach to 131I ablation therapy for the differentiated thyroid cancer
    Gortan, Fatma Arzu
    Yuksel, Alptug Ozer
    Gulaldi, Nedim Cuneyt Murat
    Coskun, Nazim
    Akca, Ceren Deniz Kapulu
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2022, 25 (03) : 260 - 268
  • [4] The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I
    Verburg, F. A.
    Verkooijen, R. B. T.
    Stokkel, M. P. M.
    van Isselt, J. W.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2009, 48 (04): : 138 - 142
  • [5] Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration
    Gomes-Lima, Cristiane J.
    Chittimoju, Sanjita
    Wehbeh, Leen
    Dia, Sunita
    Pagadala, Prathyusha
    Al-Jundi, Mohammad
    Jhawar, Sakshi
    Tefera, Eshetu
    Mete, Mihriye
    Klubo-Gwiezdzinska, Joanna
    Van Nostrand, Douglas
    Jonklaas, Jacqueline
    Wartofsky, Leonard
    Burman, Kenneth D.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2022, 6 (05)
  • [6] Comparison of 1.1 GBq and 2.2 GBq Activities in Patients with Low-Risk Differentiated Thyroid Cancer Requiring Postoperative 131I Administration: A Real Life Study
    Campenni, Alfredo
    Ruggeri, Rosaria Maddalena
    Garo, Maria Luisa
    Siracusa, Massimiliano
    Restuccia, Giovanna
    Rappazzo, Andrea
    Rosarno, Helena
    Nicocia, Antonio
    Cardile, Davide
    Ovcaricek, Petra Petranovic
    Baldari, Sergio
    Giovanella, Luca
    CANCERS, 2023, 15 (09)
  • [7] A new method to evaluate the residual activity in patients undergoing 131I thyroid therapy
    Ostinelli, A.
    Duchini, M.
    Conti, V.
    Bonfanti, P.
    Rossi, S.
    Cacciatori, M.
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2015, 31 (08): : 1108 - 1111
  • [8] Radiation dose rates of differentiated thyroid cancer patients after 131I therapy
    Jin, Pingyan
    Feng, Huijuan
    Ouyang, Wei
    Wu, Juqing
    Chen, Pan
    Wang, Jing
    Sun, Yungang
    Xian, Jialang
    Huang, Liuhua
    RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2018, 57 (02) : 169 - 177
  • [9] The radiotoxicity of 131I therapy of thyroid cancer:: Assessment by micronucleus assay of B lymphocytes
    Watanabe, N
    Kanegane, H
    Kinuya, S
    Shuke, N
    Yokoyama, K
    Kato, H
    Tomizawa, G
    Shimizu, M
    Funada, H
    Seto, H
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (04) : 608 - 611
  • [10] Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer
    Guo, Yiling
    Zhang, Yingnan
    Chen, Zuowei
    Xin, Zhenfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (05) : 1847 - 1850
1234